Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093508 · ClinicalTrials.gov registry record · Phase 1
Single-dose Safety Study of APD916 in Healthy Volunteers
A Phase 1 study of Narcolepsy With or Without Cataplexy, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT01093508: Completed Phase 1 study of Narcolepsy With or Without Cataplexy, sponsored by Arena Pharmaceuticals.
NCT01093508 is a Phase 1 study of Narcolepsy With or Without Cataplexy that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01093508, a Phase 1 study of Narcolepsy With or Without Cataplexy, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The APD916-001 study is designed primarily to evaluate the safety and tolerability of APD916 when administered as a single dose
Primary Outcome
Safety measures to include adverse events, vital signs, 12-lead ECGs, physical examinations, and clinical lab parameters.
Conditions Studied
Interventions
- DRUG APD916
Study Locations (1)
Ohio
- Community Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
What the finished NCT01093508 record still lists
NCT01093508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Narcolepsy With or Without Cataplexy appearing as the primary indexed condition, and to 1 intervention - of which APD916 is the first listed.
NCT01093508 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01093508 about?
NCT01093508 is a clinical study titled "Single-dose Safety Study of APD916 in Healthy Volunteers". The APD916-001 study is designed primarily to evaluate the safety and tolerability of APD916 when administered as a single dose
What is the current status of trial NCT01093508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2010-03. Estimated completion is 2010-07.
What conditions does trial NCT01093508 study?
This clinical trial studies the following conditions: Narcolepsy With or Without Cataplexy.
What interventions are being tested in trial NCT01093508?
The interventions under investigation include: APD916 (DRUG).
Who is sponsoring clinical trial NCT01093508?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01093508 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01093508's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia